摘要
目的比较左旋门冬酰胺酶(L-Asp)和培门冬酶(PEG-Asp)的不良反应,为临床治疗儿童急性淋巴细胞白血病(ALL)门冬酰胺酶的选择提供参考,以提高化疗中门冬酰胺酶应用的安全性。方法回顾性分析我院2012年1月一2018年6月收治的80例ALL患儿,其中44例患儿应用L-Asp方案治疗,为观察组,36例患儿应用PEG-Asp方案治疗,为对照组,对比分析两组患儿不良反应。结果两组在过敏反应、低蛋白血症及胰腺炎等不良反应差异有显著性(P <0.05)。在PT及APTT延长方面,差异无显著性(P>0.05),在纤维蛋白原降低方面,两组差异有显著性(P<0.05)。两组患儿在心肌损伤、肝功能损伤、肾功能损伤、感染及胃肠道反应等不良反应的差异无显著性(P>0.05)。结论本研究结果提示L-Asp过敏反应发生率高于PEG-Asp,PEG-Asp低蛋白血症、胰腺炎、纤维蛋白原降低等不良反应发生率高于L-Asp。两组患儿在心肌损伤、肝功能损伤、肾功能损伤、感染情况及胃肠道反应等不良反应发生率上无明显差异。
Objective This study compares the adverse reactions of L-Asparaginase and Pegaspargase,which provides a reference for the clinical treatment of children with acute lymphoblastic leukemia.Methods 80 children with acute lymphoblastic leukemia treated in our hospital from January in 2012 through June in 2018 are employed,44 cases were treated with L-Asparaginase,which is the observation group,36 cases of patients were treated with Pegaspargase(reference group).The adverse reactions are compared between the two groups by retrospective analysis.Results There are statistically significant difference between the two groups in allergic reaction,hypoproteinemia and pancreatitis.The difference between the two groups is not statistically significant in PT and APTT extension,while there are statistically significant differences in Fibrinogen reduction.The difference of adverse reactions in myocardial,liver function injury,renal function injury,infection and gastrointestinal reaction between the two groups has no statistical significance.Conclusions The results of this study suggest that the incidence of allergic reaction in L-Asparaginase group is higher than that in Pegaspargase group,the incidences of hypoproteinemia,pancreatitis,and fibrinogen reduction are higher in Pegaspargase than that in L-Asparaginase.There is no significant difference in the incidence of adverse reactions,such as myocardial injury,liver function injury,renal function injury,infection and gastrointestinal reaction between the two groups.
作者
陈力溶
王西阁
徐一卓
周玉洁
CHEN Lirong;WANG Xige;XU Yizhuo;ZHOU Yujie(Third Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《中国小儿血液与肿瘤杂志》
CAS
2019年第2期69-73,79,共6页
Journal of China Pediatric Blood and Cancer
